ORION Biotech Catalyst Calendar
Menu
Skip to company dates

Inovio Pharmaceuticals (INO) pipeline and stated timing

Name in SEC filings: INOVIO PHARMACEUTICALS, INC.

Pipeline at a glance

ProgramEventStageStated timingFiling
INO-3107 target date (company stated)PDUFAOctober 30, 202610-Q ·

Source: ORION, orionbiotechai.com/company/INO, data as of Oct 18, 2026
https://www.orionbiotechai.com/company/INO

Nearest upcoming stated timing: INO-3107 · PDUFA target date (company stated) · October 30, 2026

SEC sources last checked .

Programs and stated timing

○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.

INO-3107

Matched

PDUFA target date (company stated)October 30, 2026

Stage: PDUFASEC filing · “PDUFA) target date”

Public float: $74,300,000 · as of · SEC filing

In December 2025, the FDA accepted our BLA for INO-3107 for review under the accelerated approval program as a potential treatment for adults with RRP and set the Prescription Drug User Fee Act (PDUFA) target date for October 30, 2026.

10-Q · Filed · Last checked

Source details

Accession 0001055726-26-000023

Alert me · Calendar: same stage and window-end month (2026-10)

How this date was described over time

Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .

Program / eventStated period and SEC wordingDisclosure in stated period
INO-3107FDA decisionOctober 30, 2026
“In December 2025, the FDA accepted our BLA for INO-3107 for review under the accelerated approval program as a potential treatment for adults with RRP and set the Prescription Drug User Fee Act (PDUFA) target date for October 30, 2026.”

Filed · 10-Q

Period not started

The stated period has not started yet, so there is nothing to compare.

INO-3107FDA decisionOctober 30, 2026
“In December 2025, the FDA accepted for review the company’s BLA for INO-3107 under the accelerated approval program and set a target PDUFA date for October 30, 2026.”

Filed · EX-99.1

Period not started

The stated period has not started yet, so there is nothing to compare.

INO-3107FDA decisionOctober 30, 2026
“In December 2025, the FDA accepted our BLA for INO-3107 for review under the accelerated approval program as a potential treatment for adults with RRP and set the Prescription Drug User Fee Act (PDUFA) target date for October 30, 2026.”

Filed · 10-Q

Period not started

The stated period has not started yet, so there is nothing to compare.

“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.

Watch INO

Or email ORION to ask for this Watch.

Request another SEC timing statement

Suggest an SEC timing statement to add for INO. You can include the original filing link in your note. The founder reads each request by hand.

Or email ORION.

Reading these records

First stated window
The timing wording in the earliest company statement located within the sources checked, quoted as written (for example “2H 2026”). An earlier statement may exist outside those sources.
Disclosure date
The date of the filing or company release that disclosed the readout. “None found” means no such disclosure was located in the sources checked. SEC filings were searched through the “SEC filings searched through” date shown.
1H, 2H, 1Q–4Q
First or second half, or first to fourth quarter, of the year named, as the company wrote it. Equivalent notations are compared together; the original wording stays visible.
SEC original
The filing as published on the SEC EDGAR system. “Company original” is the release on the company's own investor site.
Status
One of seven labels set by founder review of the original filings. Definitions: Methodology.

See INO in the calendar · Review labels and methodology

A PDUFA date is the target date by which the FDA aims to decide on a drug or biologic application.